Graphite Bio Inc
NASDAQ:LENZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Graphite Bio Inc
NASDAQ:LENZ
|
US |
|
C
|
China Industrial Steel Inc
OTC:CDNN
|
US |
|
ACM Research Shanghai Inc
SSE:688082
|
CN |
|
Denison Mines Corp
TSX:DML
|
CA |
|
Frontdoor Inc
NASDAQ:FTDR
|
US |
|
Syntara Ltd
ASX:SNT
|
AU |
|
Laxmi Cotspin Ltd
NSE:LAXMICOT
|
IN |
|
O
|
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
|
US |
Graphite Bio Inc
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
